Using MIPs for medicine

– Imprinting a difference

Learn More

Welcome to MipSalus

MipSalus is dedicated to developing new, non-systemic pharmaceutical drugs for treatment of metabolic orphan diseases

New proprietary drug

MipSalus is developing a new proprietary drug – the first in a new class of medicines – for the treatment of all variants of HPA (Hyperphenylalaninemia)

LEARN MORE

The disease

Phenylketonuria (PKU) is a rare metabolic disorder. People with PKU cannot metabolize phenylalanine (Phe), an amino acid found in all kinds of dietary protein.

LEARN MORE

MANAGEMENT

NICOLAS O. KROGH
NICOLAS O. KROGHChief Executive Officer
READ MORE
KLAUS GREGORIUS
KLAUS GREGORIUSChief Scientific Officer
READ MORE
AMANDA ANDRESEN
AMANDA ANDRESENChief Operating Officer
READ MORE

BOARD OF DIRECTORS

JENS PETER TOFT
JENS PETER TOFTChairman of the Board
CLAUS BAYER
CLAUS BAYERVice Chairman of the Board
MICHAEL AHM
MICHAEL AHMBoard Member
KLAUS GREGORIUS
KLAUS GREGORIUSBoard Member
NICOLAS O. KROGH
NICOLAS O. KROGHBoard Member

ABOUT THE COMPANY

MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment for the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to prevent uptake of surplus dietary phenylalanine (Phe) in the body.

The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.